Australian Aerospace & Defense Stock News

ASX Limited has appointed Dee McGrath as a new non-executive director to its Board, effective 4 December 2025, continuing its Board renewal alongside recent additions Anne Loveridge AM and John Cincotta. With more than 30 years in global business, technology, and financial services, including leadership roles at MUFG, IBM, Visa and NAB, McGrath’s experience in large-scale transformations and regulatory change could influence how ASX approaches technology modernisation and governance in...

Electro Optic Systems Holdings recently took part in a Drone Conference, an industry gathering that showcased its counter-drone and related defense technologies to peers, customers, and analysts. This exposure can be important because such events often spotlight a company's innovation pipeline and market positioning, potentially reshaping how investors view its long-term role in unmanned systems. Now, we will explore how Electro Optic Systems Holdings’ Drone Conference participation could...

Earlier this week, James Hardie Industries appointed Jonathan Skelly as President and General Manager of its North America Building Products Group and promoted long-time executive John Madson to Chief Sales Officer, while North America President Sean Gadd chose to leave the company. The leadership reshuffle hands James Hardie’s largest market to an external hire with deep experience at AZEK and Grainger, paired with an insider sales leader who has spent over two decades building the firm’s...

In recent weeks, Fortescue Ltd expanded its green technology push by partnering with Taiyuan Iron and Steel Group on hydrogen-based plasma-enhanced low‑carbon steelmaking, while also updating investors at the Resourcing Tomorrow conference in London and issuing new employee incentive securities. Together with its latest Modern Slavery Statement and strengthened supply chain standards, these moves highlight Fortescue’s attempt to align long-term growth with decarbonisation and human rights...

Greenhy2 Limited ( ASX:H2G ) insiders who bought shares over the past year were rewarded handsomely last week. The...

Key Insights Using the 2 Stage Free Cash Flow to Equity, NRW Holdings fair value estimate is AU$8.94 Current share...

Liontown Resources recently executed a binding offtake agreement with Canmax Technologies, under which it will supply 150,000 wet metric tonnes of spodumene concentrate annually during 2027 and 2028. This long-term supply commitment broadens Liontown’s customer base across geographies and the battery value chain, reinforcing its position in the global lithium materials market. We’ll now explore how this long-term Canmax offtake agreement may influence Liontown’s investment narrative,...

Telix Pharmaceuticals (ASX:TLX) has dosed the first patient in Part 2 of its ProstACT Global Phase 3 trial for TLX591 in advanced prostate cancer, a key step that can reshape future value expectations. See our latest analysis for Telix Pharmaceuticals. This milestone comes after a tough stretch for investors, with the share price down sharply on a year to date basis even as the 3-year total shareholder return of 97.18 percent still points to strong long term wealth creation. This suggests...

Australian shares are poised for a robust start, with a projected 0.75% increase following the Federal Reserve's decision to trim U.S. rates for the third consecutive time. In this context, penny stocks—despite their somewhat outdated moniker—remain an intriguing investment area due to their potential for significant returns when backed by solid financials. This article explores three ASX penny stocks that exhibit strong financial foundations and could offer investors hidden value and growth...

With its stock down 16% over the past three months, it is easy to disregard Objective (ASX:OCL). But if you pay close...

Mineral Resources (ASX:MIN) has just popped up in a fresh ASX uptrend roundup, with its share price strength and technical signals putting it in the same conversation as the larger mining names. See our latest analysis for Mineral Resources. That recent breakout to A$51.63 caps a powerful run, with the 30 day share price return of 16.6 percent and 90 day share price return of 43.8 percent signalling momentum is building, even though the 3 year total shareholder return is still negative. If...

Hazer Group Limited ( ASX:HZR ) shareholders should be happy to see the share price up 12% in the last quarter. But...

SGH Limited ( ASX:SGH ) received a lot of attention from a substantial price movement on the ASX over the last few...

QBE Insurance Group has recently tightened climate requirements for its oil and gas clients, advanced its net zero commitments, continued expanding leadership in its UK casualty business, issued and converted 3,845 new ordinary shares, and announced that Non-Executive Director Peter Wilson will leave the board at the end of 2025 to join a competitor. Together, these moves highlight QBE’s push to sharpen climate risk oversight, deepen specialist underwriting capability in key markets, and...

Earlier in December 2025, Fitch Ratings upgraded Aristocrat Leisure’s Long-Term Issuer Default Ratings to ‘BBB’ from ‘BBB-’ with a Stable Outlook, reflecting its shift to an unsecured capital structure after repaying its term loan B. The upgrade underscores Fitch’s view that Aristocrat’s growing digital operations, strong credit metrics, and robust free cash flow generation support a more resilient balance sheet. We’ll now explore how this Fitch upgrade, particularly the move to an unsecured...

CSL recently reported five-year Phase 3 HOPE-B data in NEJM and at the ASH meeting, showing HEMGENIX’s durable factor IX activity, sustained bleed reduction, and continued freedom from routine prophylaxis in adults with hemophilia B. The results reinforce HEMGENIX’s position as the only commercially available gene therapy for adult hemophilia B, with long-term safety and efficacy data that may shape how patients and clinicians view one-time gene therapy versus ongoing prophylaxis. We’ll now...

With a price-to-sales (or "P/S") ratio of 3.3x Raiz Invest Limited ( ASX:RZI ) may be sending very bullish signals at...

It is a pleasure to report that the IODM Limited ( ASX:IOD ) is up 43% in the last quarter. But that doesn't change the...

When close to half the companies operating in the Consumer Services industry in Australia have price-to-sales ratios...

There wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.4x is worth a...

We wouldn't blame Catalyst Metals Limited ( ASX:CYL ) shareholders if they were a little worried about the fact that...

Most readers would already be aware that Whitehaven Coal's (ASX:WHC) stock increased significantly by 21% over the past...

Key Insights Tesoro Gold's significant individual investors ownership suggests that the key decisions are influenced by...

Clinuvel Pharmaceuticals (ASX:CUV) is in the spotlight after unveiling a major expansion of its Vallaurix innovation hub in Singapore. The company has announced a five year push backed by the Economic Development Board to accelerate advanced peptide drug development. See our latest analysis for Clinuvel Pharmaceuticals. The market seems to be warming to that strategy, with a 30 day share price return of 17.15% and a 90 day gain of 21.11%. However, the five year total shareholder return...